Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study

Errors occurred in the abstract of this paper by Shin and colleagues (BMJ 2024;386:e079475, doi:10.1136/bmj-2024-079475, published 28 August 2024). In the final sentence of the results section, the text should have stated: The association was greater for more than two years of treatment (hazard ratio for [not of] dementia 0.52, 95% CI 0.41 to 0.66 [not 0.57, 0.46 to 0.70] than for two years or less (0.57, 0.46 to 0.70 [not 0.52, 0.41 to 0.66] and persisted across subgroups.
Read Original Article: Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study »